Umor cost-free at the long-term survival endpoint; in contrast, the Mut-mAb
Umor absolutely free in the long-term survival endpoint; in contrast, the Mut-mAb delayed the development of CT26 cells but did not eradicate the tumors (Figure 6A). Each mAbs failed to…